arrow_back Back Filing freshness 20-F FY 2026 SEC EDGAR

China SXT Pharmaceuticals, Inc.

SXTC
$2.87 ▼ -0.23 (-7.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
11 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Neutral
auto_awesome

Analytical Summary

China SXT Pharmaceuticals, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.0M
Dividend Yield —
Revenue Growth -34.6% ↘
Op. Margin None
ROIC -18.5% ↘
FCF / Share $-5.91 ↘
Trailing P/E —
Price / Book 0.1x
FCF Yield —
Debt / Equity 0.03
info Valuation on last close. End-of-day price, Nov 5, 2026.

11-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.14M
↓ -34.6% —
Net Income Profit after all expenses
$-6.21M
↓ -87.8% —
Operating Margin Operating profit as % of sales
-154.0%
↓ -18.1% —
FCF / Share Free cash flow per share
$-5.91
↓ -258.7% —
Long-Term Debt Long-term obligations
$644.39K
↓ -20.2% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns ↑
24
Financial Health →
48
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 11 quarters